- Home
- / SCHOTT Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
SCHOTT Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
€986.2 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| EUR | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|
| Revenue | 898.6M | 957.1M | 986.2M |
| Cost of goods sold | 530.3M | 569.5M | 574.3M |
| Gross profit | 391.0M | 413.4M | 430.8M |
| Gross profit margin, % | 43.5% | 43.2% | 43.7% |
| Operating expense total | 160.1M | 156.6M | 164.3M |
| Depreciation and amortization | 51.8M | 65.0M | 79.4M |
| EBITDA | 242.7M | 269.3M | 280.4M |
| EBITDA margin, % | 27.0% | 28.1% | 28.4% |
| EBIT | 191.2M | 204.9M | 201.3M |
| EBIT margin, % | 21.3% | 21.4% | 20.4% |
| Interest income | 5.2M | 6.0M | 7.9M |
| Interest expense | 12.5M | 15.9M | 21.8M |
| Pre tax profit | 185.8M | 184.0M | 187.8M |
| Income tax expense | 33.9M | 33.6M | 40.8M |
| Net Income | 151.9M | 150.3M | 147.0M |